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Evaluating organ delineation, dose calculation
and daily localization in an open-MRI simulation
workflow for prostate cancer patients
Anthony Doemer1*, Indrin J Chetty1, Carri Glide-Hurst1, Teamour Nurushev2, David Hearshen3, Milan Pantelic3,
Melanie Traughber4, Joshua Kim1, Kenneth Levin1, Mohamed A Elshaikh1, Eleanor Walker1 and Benjamin Movsas1

Abstract
Background: This study describes initial testing and evaluation of a vertical-field open Magnetic Resonance Imaging
(MRI) scanner for the purpose of simulation in radiation therapy for prostate cancer. We have evaluated the clinical
workflow of using open MRI as a sole modality for simulation and planning. Relevant results related to MRI alignment
(vs. CT) reference dataset with Cone-Beam CT (CBCT) for daily localization are presented.
Methods: Ten patients participated in an IRB approved study utilizing MRI along with CT simulation with the intent of
evaluating the MRI-simulation process. Differences in prostate gland volume, seminal vesicles, and penile bulb were
assessed with MRI and compared to CT. To evaluate dose calculation accuracy, bulk-density-assignments were mapped
onto respective MRI datasets and treated IMRT plans were re-calculated. For image localization purposes, 400 CBCTs
were re-evaluated with MRI as the reference dataset and daily shifts compared against CBCT-to-CT registration. Planning
margins based on MRI/CBCT shifts were computed using the van Herk formalism.
Results: Significant organ contour differences were noted between MRI and CT. Prostate volumes were on average
39.7% (p = 0.002) larger on CT than MRI. No significant difference was found in seminal vesicle volumes (p = 0.454).
Penile bulb volumes were 61.1% higher on CT, without statistical significance (p = 0.074). MRI-based dose calculations
with assigned bulk densities produced agreement within 1% with heterogeneity corrected CT calculations. The differences
in shift positions for the cohort between CBCT-to-CT registration and CBCT-to-MRI registration are −0.15 ±
0.25 cm (anterior-posterior), 0.05 ± 0.19 cm (superior-inferior), and −0.01 ± 0.14 cm (left-right).
Conclusions: This study confirms the potential of using an open-field MRI scanner as primary imaging modality for
prostate cancer treatment planning simulation, dose calculations and daily image localization.
Keywords: MRI simulation, CBCT localization, MRI dose calculation, Anatomical delineation, Radiation Oncology

Background
Magnetic resonance imaging (MRI) is a supplement to
computed tomography (CT) in radiation oncology where
superior soft tissue contrast is required for anatomical
delineation. MRI simulation in radiation therapy (RT)
could potentially be a routine modality in the future primarily because MRI offers the ability to image tumors
and surrounding healthy tissues with significantly better
soft tissue contrast than CT (lung being a notable exception).
* Correspondence: adoemer1@hfhs.org
1
Department of Radiation Oncology, Henry Ford Health System, 2799 W.
Grand Blvd, Detroit, MI 48202, USA
Full list of author information is available at the end of the article

MRI is an established standard for target and organ-at-risk
delineation for brain and spinal cord cancers and is used in
conjunction with CT for treatment planning [1-3]. In prostate treatment in particular, MRI as a visualization tool for
structures has been investigated [4-7].
MRI-only workflows have been introduced with the
primary endpoint of eliminating the need for CT simulation (CT-SIM). Devic [8] provides an excellent review of
the current use of MRI in radiation oncology, including
MRI simulation. Recently, MRI-only simulators have been
introduced, incorporating features commonly found in
CT-SIM: flat table tops to accommodate immobilization
devices and external laser systems for patient marking and
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alignment. These two major additions facilitate better
agreement in patient positioning between MRI and radiation therapy delivery. As MRI technology continues to
evolve, new radiation therapy systems are utilizing MRI as
an on-board localization technology, such as the three cobalt source unit from ViewRay (Oakwood Village, OH)
[9], the MRI-LINAC from Elekta (Stockholm, SE) [10], or
the MRI-on-rails solution being installed at Princess
Margaret Hospital in Toronto, CA [11].
Nevertheless, CT-SIM remains the gold standard for
treatment planning because CT voxels demonstrate a tissue’s electron density, a factor critical to determining the
absorbed dose, as well excellent geometric accuracy and
less stringent safety considerations. Electron density information is not easily accessible from MRI; and in an
MRI-only simulation workflow treatment planners need
to assign bulk densities to multiple contours that are not
currently generated in a CT workflow. MRI treatment
planning is currently a topic of considerable interest in
radiation oncology [12-15]. Despite its promise, issues
related to geometric distortions (stemming from magnetic field inhomogeneities [16,17] and patient-induced
artifacts [18,19]), dose calculation [20-22] and the use of
MRI datasets for image-guidance need to be optimized
to facilitate accurate and efficient clinical workflow.
This study’s goal was to evaluate the potential of
vertical-field open design MRI scanner as a primary
modality for simulation, planning, and IGRT-based
localization for treatment of patients with prostate cancers. Dose calculation accuracy was evaluated, including the use of bulk density assignments to overcome
limitations in electron density conversion of the MRI
signal. A unique aspect of our study centers on using
MRI as a reference dataset for CBCT-MRI, 3D-3D
image registration for image-guided RT. Such data is
important for routine clinical use of MRI, and has not
been previously published. Additionally, for an open
platform MRI simulator, we investigated issues related
to image acquisition sequences, and the possible pitfalls
of improper imaging and its effect on anatomical contouring.

Methods
Ten prostate cancer patients enrolled on an Institutional
Review Board approved study (to be in compliance of
the Helsinki declaration) had a MRI acquired along with
standard CT simulation. MRIs were obtained from a one
Tesla (1.0 T) open MRI scanner (Panorama, Philips
Healthcare, Best, Netherlands) that has been developed
as a simulation device for RT procedures. Figure 1 shows
our workflow for CT and MRI simulation. Whole pelvis
acquisitions were performed using T1-weighted Fast Field
Echo, T2-weighted Turbo Spin Echo and 3D balanced
Turbo Field Echo (bTFE) sequences. Table 1 shows acquisition parameters for these scans. T1 and T2 scans were
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full field of view (FOV) in order to use them for treatment
planning. The bTFE scans were ‘coned-down’ to smaller
regions of interest to help keep acquisition time down and
allow for improved organ delineation. Of note is that these
acquisition parameters are optimized for RT planning by
the manufacturer, and are not applicable to diagnostic
imaging protocols. A flat table top insert (Civco, Orange
City, IA) was used to reproduce typical patient positioning.
The MRI simulation process shares many aspects with
CT simulation. The anatomy of interest (pelvis, head, etc.)
is externally targeted and then moved to the magnet isocenter. A three plane survey (analogous to CT scouts) is
performed with the largest FOV to determine the acquisition volume. Acquisition time for three whole pelvis sequences totals twenty minutes.
Anatomical contouring

All anatomical delineation and planning were done in
Eclipse® (Varian Medical Systems, Palo Alto, CA). First,
all MRIs were rigidly registered to CT images focusing
on a match of the prostate. Secondly, organ delineation
was performed/reviewed by a single observer for the T1MRI and CT images. Retrospectively, another observer
contoured the T2 and bTFE volumes. All contours were
reviewed by an attending physician.
Treatment planning

All patients were planned using intensity modulated radiation therapy (IMRT) with seven or nine fields. The
clinical target volume (CTV) was defined as prostate or
as prostate plus proximal seminal vesicles based on disease staging. For patient treatment, the prostate volume
was based on the CT volume instead of the MRI drawn
prostate volume. The planned target volume (PTV) was
an expansion of the CTV by 1 cm in all directions except 0.6 cm posteriorly. IMRT dose constraints followed
QUANTEC [23] guidelines. Plans were prescribed so the
dose to ninety-five percent of the volume (D95) was
75.6 Gy in 42 fractions.
Retrospective dose calculations were performed on
T1-MRI images using bulk-density-assignment for each
of the structures (body contour, PTV, seminal vesicles,
bladder, rectum, penile bulb and bony structure), by
assigning bony tissue to 480 Hounsfield units (HU) and
soft tissue to 0 HU (water equivalent). The bone value
(480 HU) was determined by contouring bony tissue on
CT and measuring the average CT number. Soft tissue is
comprised of fat and muscle which have HU values
slightly lower and higher than water, respectively, so we
chose to represent all soft tissue with water density. No
air pockets were present in the treated area. Had they
been present, a value of −1000 HU would have been
used. Bulk-density-assignment for dose calculation using
MRI datasets in the context of prostate cancer have been
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Figure 1 Study workflow.

used by other investigators [13,21]. MRI datasets cannot
be used to generate dose plans in Eclipse v11. Instead,
unit-density CT datasets were registered to MRI datasets
and MRI contours copied to CT to create workable datasets for dose calculation. The same beam angles, leaf
segment positions and monitor units were calculated to
isocenter. We evaluated the impact of bulk-densityassignment on IMRT optimization using a few representative datasets. Inverse planning was performed using
bulk-density-assignment and plans were compared to
those in which actual CT densities were used. For both
datasets, the identical beam arrangements, plan and
optimization parameters were used for inverse planning.
The calculated DVHs for the prostate gland, bladder and
rectum were compared.

CBCT-based treatment localization

IMRT delivery was performed on Trilogy® and Truebeam® linear accelerators (Varian Medical Systems, Palo
Alto, CA). All patients underwent daily CBCT localization
and shifts were recorded. Retrospectively, another observer
used MRI datasets as the primary reference sets, allowing
for virtual realignment of all CBCT images (~400 datasets).
MRI-CBCT registration was performed manually prioritizing alignment of the prostate-rectum interface correctly,
which is standard practice. By analyzing these shifts and
using the van Herk formalism [16], we calculated the
CTV-to-PTV margins needed for the CT and MRI reference sets. This formalism calculates the margins needed
to deliver 95% of the prescribed dose to 90% of the patient
population. It is calculated using the cohort’s inter-patient
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Table 1 MRI acquisition parameters
T2 TSE

T1 FFE

bTFE

Weighting

T2

T1

T2/T1

Acquisition

2D

3D

3D

Scan duration (min:sec)

07:13.5

07:38.8

06:18.9

TR (ms)

4563

17

5.4

TE (ms)

80

6.9

2.7

ACQ voxel (mm)

1.00/1.00/2.50

1.15/1.50/2.50

1.25/1.25/2.50

REC voxel (mm)

0.69/0.69/2.50

0.69/0.69/2.50

0.60/0.60/2.50

FOV AP (mm)

300

300

260

RL (mm)

440

440

200

FH (mm)

225

225

225

Coil selection

BodySp-XL

BodySp-XL

BodySp-XL

Flip angle (deg)

90

25

75

Orientation

axial

axial

axial

Number of Signal Averages (NSA)

1

1

2

Fat Saturation

none

none

SPIR

TSE echo spacing/shot (ms)

8.0 / 200

-

-

TFE factor

-

-

256

uncertainty (Σ) and the inter-fraction uncertainty (σ) in
the formula [24].
Margin = 2.5 Σ + 0.7 σ. We also calculated the group’s
mean error (M). The inter-patient uncertainty (Σ) is
calculated by averaging all daily shifts and then taking the
standard deviation of each patient’s average value. The interfraction uncertainty (σ) is calculated by taking the standard deviation of all daily shifts and then taking the root
mean square (RMS) of each patient’s standard deviation.

with the global maximum dose for the MRI- and
CT-based plans. Patient results are presented in Table 3.
Patient eight could not have bulk-density-assignment because a hip prosthetic did not allow for accurate contouring of femoral heads and surrounding bony tissue.
The global maximum dose differed by 1.01% between
MRI and CT plans for the patient cohort, and both the
D99 and D95 were within 0.2% of the CT-based dose
calculation.

Results

CBCT-based treatment localization

Anatomical contouring

Patient 8 was not evaluated for this section due to metal
artifacts impacting CBCT image quality. The averages
and standard deviations of daily shifts used for treatment
localization for each patient are summarized in Table 4.
The differences in shift positions for the entire cohort
between CBCT-to-CT registration and CBCT-to-MRI
registration were −0.15 ± 0.25 cm in the AP direction,
0.07 ± 0.19 cm in the SI direction and −0.01 ± 0.14 cm in
the LR direction.
The margins for the CBCT-CT registration were 0.87 cm
(AP), 0.64 cm (SI) and 0.69 cm (LR) compared to the
CBCT-MRI registration values of 1.06 cm (AP), 0.66 cm
(SI) and 0.68 cm (LR). These margin calculations show that
CBCT-MRI registration is within two millimeters of those
between CBCT-CT. The largest margin difference is in the
AP direction. This is due to bowel preparation issues at
time of MRI simulation. This issue is expanded on in the
discussion section. Imaging modality did not impact daily
localization. MRI performs as well as CT as a reference
image for registration. Figure 2 shows the capability of T1-

Volumetric differences in contours from MRI and CT
datasets are summarized in Table 2. Significant differences were noted between MRI and CT. Prostate and
penile bulb volumes were on average 39.7% (p = 0.002)
and 61.1% (p = 0.074) larger on CT than on MRI respectively. The prostate volume difference agrees well
with values from Roach et al. [25] Seminal vesicle volumes
were underestimated on the CT scan by 1.7% (p = 0.454)
compared to the volumes from MRI. CTV (prostate plus
seminal vesicles) were on average 27.5% (p = 0.002)
smaller on the MRI than they were on CT.
Treatment planning

Inverse-optimized plans using either bulk-densityassignment or CT-pixel densities have dose parameters
that differ on average by less than 0.5% which was characterized for head and neck IMRT cases by Karotki et al.
[21] We analyzed the dose to 99% and 95% of the
MRI-simulation drawn prostate (D99) and (D95) along
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Table 2 Anatomical differences between MRI and CT Datasets
Prostate

Seminal Vesicles

Penile Bulb

MRI vol (cc)

CT vol (cc)

MRI vol (cc)

CT vol (cc)

MRI vol (cc)

CT vol (cc)

MRI vol (cc)

CT vol (cc)

Patient 1

79.46

89.63

16.43

19.96

2.63

3.02

95.89

109.59

Patient 2

83.70

131.00

18.23

7.66

12.98

12.02

101.93

138.66

Patient 3

37.84

56.44

16.22

14.19

3.95

4.45

54.06

70.63

Patient 4

84.20

117.60

11.17

16.47

5.25

8.76

95.37

134.07

Patient 5

26.81

45.14

6.85

9.02

1.95

4.98

33.66

54.16

Patient 6

31.78

50.20

26.59

15.37

4.04

7.15

58.37

65.57

Patient 7

38.94

44.46

22.92

17.27

3.64

4.93

61.86

61.73

Patient 8

30.82

42.13

8.80

5.24

3.44

0.55

39.62

47.37

Patient 9

32.03

42.50

9.44

12.64

2.81

4.74

41.47

55.14

Patient 10

31.76

40.83

14.26

18.02

1.58

5.87

46.02

58.85

%Diff (CT to MRI)

39.7%

−1.7%

61.1%

27.5%

St Dev

18.5%

38.1%

96.8%

17.1%

P value

0.002

0.454

0.074

0.002

MRI for providing an image reference set for daily CBCT
by comparing the respective CT/MRI registration to the
same CBCT slice. Some CBCT-MRI registrations were performed multiple times in order to measure the reproducibility, with the registration uncertainty (standard deviation)
being 0.08, 0.09 and 0.07 cm in the AP, SI and LR directions, respectively.

Discussion
We found clear visual improvement in anatomical delineation from MRI as seen by the agreement of our volume differences compared to the literature [25]. The
penile bulb is often difficult to discern on CT. The difference, both spatial and volumetric, between the MRI
volume and the CT volume are stark. Consequently, if

CTV (prostate + seminal vesicles)

using only CT, we would not be able to offer reduction
of the collateral radiation damage to these structures
during radiation planning and delivery, which may alter
the quality of life of patients treated with radiation.
A novel aspect of our study was using MRI as the reference dataset for 3D-3D CBCT-MRI matching for
image-guided RT. Such data has not been previously reported for the prostate. Since patients underwent CT
and MRI simulation, we could compare the shifts and
calculated planning margins obtained with the both datasets. Looking closely at each patient, differences in shifts between MRI and CT registration (Table 4) are consistent
overall for each modality. The only registration difference
greater than 3 mm between CT and MRI is for patient 7 in
the AP direction. This is due to non-compliance of bowel

Table 3 Dose differences between CT-based dose calculation and MRI bulk density assigned dose calculation
Plan Max Dose

D99 for Prostate

D95 for Prostate

MRI (Gy)

CT (Gy)

MRI (Gy)

CT (Gy)

MRI (Gy)

CT (Gy)

Patient 1

76.61

76.97

72.45

73.70

72.65

73.90

Patient 2

82.43

79.58

77.58

76.05

77.82

76.30

Patient 3

76.17

74.01

70.24

69.78

70.60

70.18

Patient 4

74.81

75.17

70.83

69.10

71.15

70.89

Patient 5

74.25

75.13

70.54

72.01

70.73

72.09

Patient 6

78.02

77.05

73.80

73.76

73.94

73.92

Patient 7

78.78

77.46

73.67

73.42

73.81

73.55

Patient 9

81.59

79.62

76.77

75.77

76.98

75.95

Patient 10

74.97

75.25

70.63

72.03

70.70

72.13

Avg Dose Diff.

−1.01%

−0.11%

0.12%

STDEV

1.69%

−0.34%

−0.09%

P value

0.104

0.816

0.873
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Table 4 Average and standard deviations values for CBCT shifts for all fractions
CT registered to CBCT

MRI registered to CBCT

AP (cm)

SI (cm)

LR (cm)

AP (cm)

SI (cm)

LR (cm)

Patient 1

0.21 ± 0.28

0.04 ± 0.25

0.04 ± 0.29

−0.07 ± 0.25

0.11 ± 0.11

0.03 ± 0.27

Patient 2

0.49 ± 0.30

−0.02 ± 0.54

0.07 ± 0.36

0.44 ± 0.28

0.03 ± 0.54

0.04 ± 0.33

Patient 3

0.04 ± 0.61

0.06 ± 0.53

0.06 ± 0.51

0.01 ± 0.76

0.23 ± .58

0.01 ± 0.48

Patient 4

0.10 ± 0.23

0.18 ± 0.24

−0.08 ± 0.26

0.02 ± 0.15

0.02 ± 0.15

0.00 ± 0.00

Patient 5

0.17 ± 0.32

0.28 ± 0.22

−0.06 ± 0.36

0.27 ± 0.47

0.42 ± 0.27

−0.15 ± 0.38

Patient 6

0.26 ± 0.42

0.02 ± 0.24

0.16 ± 0.19

−0.02 ± 0.33

0.10 ± 0.20

0.10 ± 0.18

Patient 7

−0.06 ± 0.49

−0.18 ± 0.88

0.11 ± 0.64

−0.63 ± 0.49

−0.11 ± 0.86

0.15 ± 0.64

Patient 9

−0.33 ± 0.28

−0.10 ± 0.16

0.30 ± 0.25

−0.28 ± 0.29

−0.02 ± 0.11

0.29 ± 0.27

Patient 10

0.36 ± 0.30

0.05 ± 0.15

−0.32 ± 0.31

0.19 ± 0.29

0.04 ± 0.14

−0.31 ± 0.33

M

0.14

0.04

0.03

−0.01

0.09

0.02

Σ

0.24

0.14

0.17

0.31

0.15

0.17

σ

0.38

0.43

0.38

0.41

0.41

0.36

Margin

0.87

0.64

0.69

1.06

0.66

0.68

0.85

0.53

0.67

0.84

0.57

0.64

†

Margin

M is the mean group error, Σ is the inter-patient uncertainty and σ is the inter-fraction uncertainty. The sigma values are used to calculate the needed CTV-PTV
margin using the van Herk formalism.
†
Margin not including patient 7, see discussion section.

preparation at the MRI and CT simulations. Due to noncompliance, the prostate position relative to bony anatomy
changed significantly. Consequently this dramatically impacts registering the CT and MRI images, particularly in
the AP direction, which resulted in systematic differences
(>6 mm) between MRI and CT-generated shifts. If we exclude this outlier data from the analysis, the margins are
nearly identical between MR and CT, as observed in Table 4.
A previous 3D-3D CBCT-MRI matching study performed
by Buhl et al. [26] reported on CBCT shifts compared to
reference MRI images of the brain and showed mean and
standard deviation values of 0.8 ± 0.6 mm, 1.5 ± 1.2 mm
and 1.2 ± 1.2 mm differences in the AP, SI and LR directions, respectively. These compare very well to our patient
cohort mean and standard deviation values of 1.5 ± 2.5 mm
in the AP direction, 0.7 ± 1.9 mm in the SI direction and
−0.1 ± 1.4 mm in the LR direction.
One disadvantage of the study was that we could not
simulate both MRI and CT during the same appointment

session. Since patients had to return for another image acquisition there were instances where rectal/bladder filling
was inconsistent between sessions. This created a source
of uncertainty during the image registration process since
changes in bladder and rectum filling could deform other
organs such as the seminal vesicles or prostate. In the clinical implementation of a MRI-only workflow, this source of
error would be mitigated.
During our study, we spent a great deal of effort outlining
the femoral heads and pelvic bones. MRI simulation and
treatment planning relies on correctly delineating all structures since bulk electron densities are assigned. We found
normal T1 and T2 image acquisitions provided substandard
image quality to properly delineate these bones. bTFE acquisition provided adequate image quality at the expense of
additional scan time. Inverting the T1 image grayscale gave
a clearer outline of the edge of the femoral heads and other
bony structures compared to T1 and T2 images. Image
comparisons can be seen in Figure 3. Future utilization of

Figure 2 Registration overlays of CBCT with either CT (on the left) or MRI (on the right).

Doemer et al. Radiation Oncology (2015) 10:37

Page 7 of 9

Figure 3 Different imaging sequences comparing bone boundaries. Detailed Legend: Imaging sequence from top left going clockwise. CT,
bTFE, Inverted T1, T1. Notice that boundary of the femoral heads and other bony tissue shows up as a region of no signal in the bTFE and T1
image. On the CT and the inverted T1 image, this edge is readily identifiable.

ultra-fast (UTE) [22] and water/fat separating multiecho (mDIXON) [27] sequences are likely necessary
for proper identification of bony anatomy. Image registration to the daily CBCT was found to be straightforward
and uncomplicated. Aligning the capsule edge, seminal
vesicles, rectum interface and the femoral heads was no
more difficult than with a CT reference image.
MRI simulation is not without limitations. The first
consideration with MRI simulation is whether to use
open or closed bore systems. Closed bore systems allow
for greater magnet strength, useful for MRI spectroscopy
and reducing overall scan time. Open-bore systems consist of 2 horizontal magnets. This open design allows for
greater patient comfort and allows simulation therapists
increased access to patients, just as in CT simulation.
However, as open-bore systems tend to use lower strength
magnets which can adversely impact the signal-to-noise
ratio. Our open-MRI system uses rigid radiofrequency
(RF) coils with integrated solenoid technology and receiver
elements perpendicular to the body’s long axis. These are
mounted to the patient table to improve the signal-tonoise ratio. Using these coils allows our 1.0 T vertical system to maximize image quality. Enders et al. [28] found
out that in a blinded randomized study evaluating vertical
and horizontal field image quality, closed-bore systems
had better image quality, though open-bore systems still
had an average image quality grade of ‘moderate’, which
is acceptable in non-diagnostic environments. The last
consideration in bore style is the need to accommodate
immobilization devices that are increasingly utilized in radiation oncology departments in order to fixate patients and
minimize patient motion during simulation and subsequent
treatment. Open-bore systems are more accommodating to
a wider arrange of immobilization devices.
Magnetic field distortions may cause geometric aberrations that can result in inaccurate identification of

the patient’s skin contour, a crucial component to radiation treatment planning [16,17]. It is important that
geometric distortions of each MRI scanner used for
simulation be characterized so that associated uncertainties across the FOV are understood [29,30]. Geometric distortions are classified as system distortions
or object-related distortions. Geometric distortion is
evaluated at our institution on a daily basis for all
three axes using a vendor provided 2-dimensional geometric distortion phantom with a field of view (FOV)
encompassing imaging sequence (~35 cm x 40 cm).
The difference in center of mass position between the
acquired image and the ideal position map is measured. Deviations are displayed as isocurves that delineate 2 mm distortion within the primary FOV up to
6 mm of distortion at the FOV edge. The plot is visually inspected to insure the 2 mm isocurve does not
advance past the peripheral imaging region. Objectrelated distortions are another concern and cannot be
evaluated with the use of a phantom. Multiple proposals exist for assessing and minimizing objectrelated distortion [18,19,31-33], but the issue remains
uncorrected in clinical settings. Distortions due to tissue susceptibility scale almost linearly with the B0 field
strength, and can be considered to be minimal (<0.5 mm)
at a field strength of 1.0 T [31]. Relative to CT, uncorrected
MRI geometric uncertainties can degrade contouring accuracy while the enhanced soft-tissue contrast improves contouring precision.
Electron density information will always be necessary
for accurate dose calculation. For this study only two
densities were assigned, but in other areas of the body
where air pockets or other tissue densities exist, this
could be a bottleneck for treatment planning efficiency
without intelligent autosegmentation tools. For MRIonly simulation, we will need to quickly and accurately
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determine a tissue’s electron density. One possibility is
to create so-called “synthetic CTs”, which are currently being researched to infer electron density information directly from MRI [21,34]. For metallic
implants such as hip prostheses, CT can use scatter
correction algorithms to correct for this presence [35],
whereas MRI is compromised by the metal artifact
and could represent a contraindication for MRI-only
simulation. Additional safety concerns need to be
thoroughly investigated and due diligence performed;
any medical product introduced into a high magnetic field
environment must be properly vetted. Examples include
implanted medical devices and infusion catheters. Our
clinic found it necessary to complete MRI screening forms
with the patients three times prior to simulation in order
to guarantee that incompatible materials do not enter
the magnetic field. Patients that are non-compliant in
this regard cannot currently be simulated in a MRI-only
simulation workflow.

Conclusion
This study confirms that MRI has the potential to be a
primary imaging modality for treatment planning
simulation, dose calculations, and daily image localization.
Readily available radiation oncology directed MR
simulation can increase the population of patients that
take advantage of more precise tumor delineation
given the improved soft tissue contrast with MRI.
Consequently it is possible to develop more accurate
treatment plans, which have the potential to positively
influence patient outcomes. Ultimately this hypothesis
needs to be tested, and in this regard, we are currently
performing a prospective clinical trial to correlate patient
outcomes (toxicities and tumor control) with dose
distributions generated using MRI-defined targets.
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